In August 2018, SpringWorks and BeiGene entered into a global clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of combining BeiGene’s investigational RAF-dimer inhibitor, lifirafenib (BGB-283) with SpringWorks Therapeutics’ investigational MEK inhibitor, mirdametinib, in a range of genetically-defined solid tumors. A Phase 1b clinical trial is enrolling patients with advanced solid tumors that harbor mutations in RAS, RAF, and other MAPK pathway genes.
In June 2019, BeiGene and SpringWorks announced the formation of MapKure, LLC, an entity that is jointly owned by BeiGene and SpringWorks. MapKure intends to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations and RAF fusions. These mutations and fusions have been identified in a number of solid tumors to be drivers of cancer growth, including in non-small cell lung cancer, colorectal cancer, thyroid cancer and brain tumors.
In June 2019, SpringWorks and GlaxoSmithKline entered into a global clinical collaboration agreement to conduct a Phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the combining SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat with GlaxoSmithKline’s investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), belantamab mafodotin (formerly GSK2857916), in patients with relapsed or refractory multiple myeloma.